CA2507189C - Fragmentation-based methods and systems for sequence variation detection and discovery - Google Patents
Fragmentation-based methods and systems for sequence variation detection and discovery Download PDFInfo
- Publication number
- CA2507189C CA2507189C CA2507189A CA2507189A CA2507189C CA 2507189 C CA2507189 C CA 2507189C CA 2507189 A CA2507189 A CA 2507189A CA 2507189 A CA2507189 A CA 2507189A CA 2507189 C CA2507189 C CA 2507189C
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- nucleic acid
- cleavage
- mass
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 261
- 238000013467 fragmentation Methods 0.000 title abstract description 99
- 238000006062 fragmentation reaction Methods 0.000 title abstract description 99
- 238000001514 detection method Methods 0.000 title description 63
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 48
- 238000003776 cleavage reaction Methods 0.000 claims description 317
- 150000007523 nucleic acids Chemical class 0.000 claims description 293
- 239000012634 fragment Substances 0.000 claims description 272
- 230000007017 scission Effects 0.000 claims description 238
- 108020004414 DNA Proteins 0.000 claims description 233
- 102000053602 DNA Human genes 0.000 claims description 230
- 102000039446 nucleic acids Human genes 0.000 claims description 225
- 108020004707 nucleic acids Proteins 0.000 claims description 225
- 125000003729 nucleotide group Chemical group 0.000 claims description 146
- 239000002521 compomer Substances 0.000 claims description 143
- 239000002773 nucleotide Substances 0.000 claims description 131
- 230000035772 mutation Effects 0.000 claims description 70
- 238000001228 spectrum Methods 0.000 claims description 70
- 238000013518 transcription Methods 0.000 claims description 65
- 230000035897 transcription Effects 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 58
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
- 201000010099 disease Diseases 0.000 claims description 44
- 238000003780 insertion Methods 0.000 claims description 33
- 230000037431 insertion Effects 0.000 claims description 33
- 102000006382 Ribonucleases Human genes 0.000 claims description 32
- 108010083644 Ribonucleases Proteins 0.000 claims description 32
- 238000012217 deletion Methods 0.000 claims description 32
- 230000037430 deletion Effects 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 29
- 238000006467 substitution reaction Methods 0.000 claims description 27
- 230000002829 reductive effect Effects 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 21
- 230000004048 modification Effects 0.000 claims description 20
- 238000012986 modification Methods 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 18
- 238000005259 measurement Methods 0.000 claims description 17
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims description 16
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 201000008827 tuberculosis Diseases 0.000 claims description 11
- 230000008995 epigenetic change Effects 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
- 241000186364 Mycobacterium intracellulare Species 0.000 claims description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 108020005403 ribonuclease U2 Proteins 0.000 claims description 5
- 241000186367 Mycobacterium avium Species 0.000 claims description 4
- 241000186363 Mycobacterium kansasii Species 0.000 claims description 4
- 238000003205 genotyping method Methods 0.000 claims description 4
- 241000287828 Gallus gallus Species 0.000 claims description 3
- 241000187484 Mycobacterium gordonae Species 0.000 claims description 3
- 108010046983 Ribonuclease T1 Proteins 0.000 claims description 3
- 241000194022 Streptococcus sp. Species 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 241000186046 Actinomyces Species 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241001148536 Bacteroides sp. Species 0.000 claims description 2
- 241000589994 Campylobacter sp. Species 0.000 claims description 2
- 241000193468 Clostridium perfringens Species 0.000 claims description 2
- 241000193449 Clostridium tetani Species 0.000 claims description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 claims description 2
- 241000186249 Corynebacterium sp. Species 0.000 claims description 2
- 241000194032 Enterococcus faecalis Species 0.000 claims description 2
- 241001495410 Enterococcus sp. Species 0.000 claims description 2
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 claims description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 2
- 241000588915 Klebsiella aerogenes Species 0.000 claims description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 2
- 241000589248 Legionella Species 0.000 claims description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 2
- 241000589902 Leptospira Species 0.000 claims description 2
- 241000186779 Listeria monocytogenes Species 0.000 claims description 2
- 241000588650 Neisseria meningitidis Species 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 241001478880 Streptobacillus moniliformis Species 0.000 claims description 2
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 2
- 241000194049 Streptococcus equinus Species 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 2
- 241000589886 Treponema Species 0.000 claims description 2
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 108010082351 cusativin Proteins 0.000 claims description 2
- 229940092559 enterobacter aerogenes Drugs 0.000 claims description 2
- 238000004393 prognosis Methods 0.000 claims description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 2
- 241000206602 Eukaryota Species 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims 1
- 238000004374 forensic analysis Methods 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 81
- 108090000623 proteins and genes Proteins 0.000 description 132
- 108090000765 processed proteins & peptides Proteins 0.000 description 105
- 102000004196 processed proteins & peptides Human genes 0.000 description 86
- 238000006243 chemical reaction Methods 0.000 description 85
- 108091093088 Amplicon Proteins 0.000 description 84
- 102000004169 proteins and genes Human genes 0.000 description 83
- 239000000523 sample Substances 0.000 description 79
- 230000000875 corresponding effect Effects 0.000 description 77
- 229920001184 polypeptide Polymers 0.000 description 77
- 235000018102 proteins Nutrition 0.000 description 76
- 102000040430 polynucleotide Human genes 0.000 description 63
- 108091033319 polynucleotide Proteins 0.000 description 63
- 239000002157 polynucleotide Substances 0.000 description 63
- 229920002477 rna polymer Polymers 0.000 description 63
- 108090000790 Enzymes Proteins 0.000 description 58
- 102000004190 Enzymes Human genes 0.000 description 57
- 229940088598 enzyme Drugs 0.000 description 57
- 239000003153 chemical reaction reagent Substances 0.000 description 53
- 150000001413 amino acids Chemical class 0.000 description 47
- 238000003752 polymerase chain reaction Methods 0.000 description 47
- 239000000047 product Substances 0.000 description 47
- 235000001014 amino acid Nutrition 0.000 description 45
- 229940024606 amino acid Drugs 0.000 description 45
- 230000011987 methylation Effects 0.000 description 44
- 238000007069 methylation reaction Methods 0.000 description 44
- 108700028369 Alleles Proteins 0.000 description 43
- 102000054765 polymorphisms of proteins Human genes 0.000 description 39
- 238000004422 calculation algorithm Methods 0.000 description 37
- 108091092878 Microsatellite Proteins 0.000 description 33
- 238000001819 mass spectrum Methods 0.000 description 33
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 31
- 230000008569 process Effects 0.000 description 31
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 30
- 230000006870 function Effects 0.000 description 28
- 238000012545 processing Methods 0.000 description 27
- 102000004533 Endonucleases Human genes 0.000 description 24
- 108010042407 Endonucleases Proteins 0.000 description 24
- 239000002253 acid Substances 0.000 description 24
- 238000012163 sequencing technique Methods 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 23
- 230000003321 amplification Effects 0.000 description 22
- 239000000872 buffer Substances 0.000 description 22
- 238000003199 nucleic acid amplification method Methods 0.000 description 22
- -1 nucleoside triphosphates Chemical class 0.000 description 22
- 108091034117 Oligonucleotide Proteins 0.000 description 21
- 230000002068 genetic effect Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 108091008146 restriction endonucleases Proteins 0.000 description 19
- 241000894007 species Species 0.000 description 19
- 239000001226 triphosphate Substances 0.000 description 19
- 108091005461 Nucleic proteins Proteins 0.000 description 18
- 230000008859 change Effects 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 235000011178 triphosphate Nutrition 0.000 description 18
- 108020004465 16S ribosomal RNA Proteins 0.000 description 16
- 150000007513 acids Chemical class 0.000 description 16
- 238000013459 approach Methods 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000002255 enzymatic effect Effects 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 14
- 239000011159 matrix material Substances 0.000 description 14
- 230000036961 partial effect Effects 0.000 description 14
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 14
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 13
- 102000035195 Peptidases Human genes 0.000 description 13
- 108091005804 Peptidases Proteins 0.000 description 13
- 230000001419 dependent effect Effects 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- 230000002441 reversible effect Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 239000011324 bead Substances 0.000 description 12
- 229920001222 biopolymer Polymers 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 108020001738 DNA Glycosylase Proteins 0.000 description 11
- 102000028381 DNA glycosylase Human genes 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 11
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 11
- 244000005700 microbiome Species 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 229950010342 uridine triphosphate Drugs 0.000 description 11
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 11
- 239000004365 Protease Substances 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 229920002521 macromolecule Polymers 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 238000004088 simulation Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 9
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 9
- 241000233866 Fungi Species 0.000 description 9
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 9
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 9
- 229910052770 Uranium Inorganic materials 0.000 description 9
- 239000012472 biological sample Substances 0.000 description 9
- 238000004891 communication Methods 0.000 description 9
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 9
- 229940104302 cytosine Drugs 0.000 description 9
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 108091029430 CpG site Proteins 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 230000003750 conditioning effect Effects 0.000 description 8
- 238000007405 data analysis Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 7
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 7
- 108060002716 Exonuclease Proteins 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 102000013165 exonuclease Human genes 0.000 description 7
- 238000001502 gel electrophoresis Methods 0.000 description 7
- 102000054766 genetic haplotypes Human genes 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 7
- BRARRAHGNDUELT-UHFFFAOYSA-N 3-hydroxypicolinic acid Chemical compound OC(=O)C1=NC=CC=C1O BRARRAHGNDUELT-UHFFFAOYSA-N 0.000 description 6
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- 102000007079 Peptide Fragments Human genes 0.000 description 6
- 108010033276 Peptide Fragments Proteins 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- 108091029523 CpG island Proteins 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 5
- 102000016911 Deoxyribonucleases Human genes 0.000 description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 description 5
- 108010059378 Endopeptidases Proteins 0.000 description 5
- 102000005593 Endopeptidases Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 208000026350 Inborn Genetic disease Diseases 0.000 description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 101710137500 T7 RNA polymerase Proteins 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000001360 collision-induced dissociation Methods 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 5
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 5
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000005546 dideoxynucleotide Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 208000016361 genetic disease Diseases 0.000 description 5
- 238000000126 in silico method Methods 0.000 description 5
- 230000005291 magnetic effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- CLGFIVUFZRGQRP-UHFFFAOYSA-N 7,8-dihydro-8-oxoguanine Chemical compound O=C1NC(N)=NC2=C1NC(=O)N2 CLGFIVUFZRGQRP-UHFFFAOYSA-N 0.000 description 4
- 208000035657 Abasia Diseases 0.000 description 4
- BXTVQNYQYUTQAZ-UHFFFAOYSA-N BNPS-skatole Chemical compound N=1C2=CC=CC=C2C(C)(Br)C=1SC1=CC=CC=C1[N+]([O-])=O BXTVQNYQYUTQAZ-UHFFFAOYSA-N 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108091027757 Deoxyribozyme Proteins 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- 101150002416 Igf2 gene Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 101100390562 Mus musculus Fen1 gene Proteins 0.000 description 4
- 241000187494 Mycobacterium xenopi Species 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 101100119953 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) fen gene Proteins 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 4
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 4
- 239000005547 deoxyribonucleotide Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000007614 genetic variation Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000012804 iterative process Methods 0.000 description 4
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000009145 protein modification Effects 0.000 description 4
- 125000002652 ribonucleotide group Chemical group 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 3
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 241000588807 Bordetella Species 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 230000007067 DNA methylation Effects 0.000 description 3
- 102000002494 Endoribonucleases Human genes 0.000 description 3
- 108010093099 Endoribonucleases Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010085220 Multiprotein Complexes Proteins 0.000 description 3
- 102000007474 Multiprotein Complexes Human genes 0.000 description 3
- 241000186359 Mycobacterium Species 0.000 description 3
- 241001134667 Mycobacterium celatum Species 0.000 description 3
- 241000187492 Mycobacterium marinum Species 0.000 description 3
- 108010010677 Phosphodiesterase I Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- 102100036407 Thioredoxin Human genes 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 229960000789 guanidine hydrochloride Drugs 0.000 description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- 229940063673 spermidine Drugs 0.000 description 3
- 108010068698 spleen exonuclease Proteins 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- CQMJEZQEVXQEJB-UHFFFAOYSA-N 1-hydroxy-1,3-dioxobenziodoxole Chemical compound C1=CC=C2I(O)(=O)OC(=O)C2=C1 CQMJEZQEVXQEJB-UHFFFAOYSA-N 0.000 description 2
- XHBSBNYEHDQRCP-UHFFFAOYSA-N 2-amino-3-methyl-3,7-dihydro-6H-purin-6-one Chemical compound O=C1NC(=N)N(C)C2=C1N=CN2 XHBSBNYEHDQRCP-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- NQUNIMFHIWQQGJ-UHFFFAOYSA-N 2-nitro-5-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC(SC#N)=CC=C1[N+]([O-])=O NQUNIMFHIWQQGJ-UHFFFAOYSA-N 0.000 description 2
- ZPBYVFQJHWLTFB-UHFFFAOYSA-N 3-methyl-7H-purin-6-imine Chemical compound CN1C=NC(=N)C2=C1NC=N2 ZPBYVFQJHWLTFB-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 108090000915 Aminopeptidases Proteins 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101150069040 CETP gene Proteins 0.000 description 2
- 101100322581 Caenorhabditis elegans add-1 gene Proteins 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 108700034637 EC 3.2.-.- Proteins 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101710113436 GTPase KRas Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 241000700739 Hepadnaviridae Species 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 2
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 2
- 101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000187473 Mycobacterium aurum Species 0.000 description 2
- 241000187478 Mycobacterium chelonae Species 0.000 description 2
- 241001467535 Mycobacterium interjectum Species 0.000 description 2
- 241000520094 Mycobacterium paraffinicum Species 0.000 description 2
- 241000187480 Mycobacterium smegmatis Species 0.000 description 2
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 241000701945 Parvoviridae Species 0.000 description 2
- 201000009928 Patau syndrome Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000032236 Predisposition to disease Diseases 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 101710118538 Protease Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000006093 RNA methylation Effects 0.000 description 2
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 2
- 230000007022 RNA scission Effects 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010044686 Trisomy 13 Diseases 0.000 description 2
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 208000026928 Turner syndrome Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000011203 antimicrobial therapy Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 108010002712 deoxyribonuclease II Proteins 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical group [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 2
- 229940066758 endopeptidases Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- NKKLCOFTJVNYAQ-UHFFFAOYSA-N formamidopyrimidine Chemical compound O=CNC1=CN=CN=C1 NKKLCOFTJVNYAQ-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 102000053400 human TPO Human genes 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 235000013919 monopotassium glutamate Nutrition 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108010066823 proline dipeptidase Proteins 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 239000002719 pyrimidine nucleotide Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102000037983 regulatory factors Human genes 0.000 description 2
- 108091008025 regulatory factors Proteins 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 206010053884 trisomy 18 Diseases 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QSLFDILMORXPKP-UHFFFAOYSA-N (3-methylimidazol-3-ium-1-yl)-methylsulfanylphosphinate Chemical compound CSP([O-])(=O)N1C=C[N+](C)=C1 QSLFDILMORXPKP-UHFFFAOYSA-N 0.000 description 1
- HCUOEKSZWPGJIM-YBRHCDHNSA-N (e,2e)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N/O)\C(N)=O HCUOEKSZWPGJIM-YBRHCDHNSA-N 0.000 description 1
- WWJWZQKUDYKLTK-UHFFFAOYSA-N 1,n6-ethenoadenine Chemical compound C1=NC2=NC=N[C]2C2=NC=CN21 WWJWZQKUDYKLTK-UHFFFAOYSA-N 0.000 description 1
- PQMRRAQXKWFYQN-UHFFFAOYSA-N 1-phenyl-2-sulfanylideneimidazolidin-4-one Chemical group S=C1NC(=O)CN1C1=CC=CC=C1 PQMRRAQXKWFYQN-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- NIJSNUNKSPLDTO-DJLDLDEBSA-N 2'-deoxytubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 NIJSNUNKSPLDTO-DJLDLDEBSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- QSECPQCFCWVBKM-UHFFFAOYSA-N 2-iodoethanol Chemical compound OCCI QSECPQCFCWVBKM-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- LQGNCUXDDPRDJH-UHFFFAOYSA-N 3'-GMP Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)C)CCC33O)C)C3=CC(=O)C21 LQGNCUXDDPRDJH-UHFFFAOYSA-N 0.000 description 1
- 108010037497 3'-nucleotidase Proteins 0.000 description 1
- 108010034927 3-methyladenine-DNA glycosylase Proteins 0.000 description 1
- CUVGUPIVTLGRGI-UHFFFAOYSA-N 4-(3-phosphonopropyl)piperazine-2-carboxylic acid Chemical compound OC(=O)C1CN(CCCP(O)(O)=O)CCN1 CUVGUPIVTLGRGI-UHFFFAOYSA-N 0.000 description 1
- JNQYNXFGVRUFNP-JGVFFNPUSA-N 4-amino-1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)CC1 JNQYNXFGVRUFNP-JGVFFNPUSA-N 0.000 description 1
- WJWWDONJARAUPN-UHFFFAOYSA-N 4-anilino-5h-1,3-thiazol-2-one Chemical compound O=C1SCC(NC=2C=CC=CC=2)=N1 WJWWDONJARAUPN-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- MREZUWMZVPBIEE-CAHLUQPWSA-N 5-bromo-1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C(Br)=C1 MREZUWMZVPBIEE-CAHLUQPWSA-N 0.000 description 1
- JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 description 1
- NGYHUCPPLJOZIX-XLPZGREQSA-N 5-methyl-dCTP Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NGYHUCPPLJOZIX-XLPZGREQSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000001921 Aminopeptidase P Human genes 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101150054111 Aspg gene Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- 201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 241000588851 Bordetella avium Species 0.000 description 1
- 241000359246 Bordetella petrii Species 0.000 description 1
- 241000543043 Bordetella trematum Species 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- 102100031866 DNA excision repair protein ERCC-5 Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 101710150423 DNA nickase Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102100029094 DNA repair endonuclease XPF Human genes 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000010719 DNA-(Apurinic or Apyrimidinic Site) Lyase Human genes 0.000 description 1
- 108010063362 DNA-(Apurinic or Apyrimidinic Site) Lyase Proteins 0.000 description 1
- 108010060616 DNA-3-methyladenine glycosidase II Proteins 0.000 description 1
- 108010000577 DNA-Formamidopyrimidine Glycosylase Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010046855 DNA-deoxyinosine glycosidase Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- OFDYMSKSGFSLLM-UHFFFAOYSA-N Dinitramine Chemical compound CCN(CC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C(N)=C1[N+]([O-])=O OFDYMSKSGFSLLM-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 201000006360 Edwards syndrome Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical class [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 1
- 102100026121 Flap endonuclease 1 Human genes 0.000 description 1
- 108090000652 Flap endonucleases Proteins 0.000 description 1
- 108050007570 GTP-binding protein Rad Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000834713 Gogo Species 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- 101000913035 Homo sapiens Flap endonuclease 1 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 1
- MTFVYKQRLXYAQN-LAEOZQHASA-N Ile-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O MTFVYKQRLXYAQN-LAEOZQHASA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- GHSJKUNUIHUPDF-BYPYZUCNSA-N L-thialysine Chemical group NCCSC[C@H](N)C(O)=O GHSJKUNUIHUPDF-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000203407 Methanocaldococcus jannaschii Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108091092919 Minisatellite Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 208000016679 Monosomy X Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001508003 Mycobacterium abscessus Species 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101710149004 Nuclease P1 Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- GNADVDLLGVSXLS-ULQDDVLXSA-N Pro-Phe-His Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O GNADVDLLGVSXLS-ULQDDVLXSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000205156 Pyrococcus furiosus Species 0.000 description 1
- 241000205192 Pyrococcus woesei Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 108091061939 Selfish DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 102100024855 Three-prime repair exonuclease 1 Human genes 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 101150045640 VWF gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 108010038900 X-Pro aminopeptidase Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 101150044453 Y gene Proteins 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 108010054847 carboxypeptidase P Proteins 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229940105784 coagulation factor xiii Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- ZDPUTNZENXVHJC-UHFFFAOYSA-N cumingianoside D Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(OP(O)(O)=O)C1O ZDPUTNZENXVHJC-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 108010039178 deoxynucleotide 3'-phosphatase Proteins 0.000 description 1
- 230000027832 depurination Effects 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- 238000013104 docking experiment Methods 0.000 description 1
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- ZDPUTNZENXVHJC-UUOKFMHZSA-L guanosine 3'-monophosphate(2-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP([O-])([O-])=O)[C@H]1O ZDPUTNZENXVHJC-UUOKFMHZSA-L 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000004731 long QT syndrome Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- STEPQTYSZVCJPV-UHFFFAOYSA-N metazachlor Chemical compound CC1=CC=CC(C)=C1N(C(=O)CCl)CN1N=CC=C1 STEPQTYSZVCJPV-UHFFFAOYSA-N 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 208000029140 neonatal diabetes Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 238000003976 plant breeding Methods 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- BNYAFRXGLZQIHA-LDJKHGTPSA-J tetralithium [[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate Chemical compound [Li+].P([O-])(=O)(OP(=O)([O-])OP(=O)([O-])[O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C(=O)NC(=O)C(=C1)C)O)O.[Li+].[Li+].[Li+] BNYAFRXGLZQIHA-LDJKHGTPSA-J 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 102000055046 tissue-factor-pathway inhibitor 2 Human genes 0.000 description 1
- 108010016054 tissue-factor-pathway inhibitor 2 Proteins 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241000724775 unclassified viruses Species 0.000 description 1
- 241001300301 uncultured bacterium Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6872—Methods for sequencing involving mass spectrometry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Wood Science & Technology (AREA)
- Theoretical Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Electron Tubes For Measurement (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42989502P | 2002-11-27 | 2002-11-27 | |
| US60/429,895 | 2002-11-27 | ||
| PCT/US2003/037931 WO2004050839A2 (en) | 2002-11-27 | 2003-11-26 | Fragmentation-based methods and systems for sequence variation detection and discovery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2507189A1 CA2507189A1 (en) | 2004-06-17 |
| CA2507189C true CA2507189C (en) | 2018-06-12 |
Family
ID=32469386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2507189A Expired - Fee Related CA2507189C (en) | 2002-11-27 | 2003-11-26 | Fragmentation-based methods and systems for sequence variation detection and discovery |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7820378B2 (https=) |
| EP (1) | EP1613723B1 (https=) |
| JP (1) | JP4786904B2 (https=) |
| CN (1) | CN1774511B (https=) |
| AU (1) | AU2003298733B2 (https=) |
| CA (1) | CA2507189C (https=) |
| WO (1) | WO2004050839A2 (https=) |
Families Citing this family (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6994969B1 (en) * | 1999-04-30 | 2006-02-07 | Methexis Genomics, N.V. | Diagnostic sequencing by a combination of specific cleavage and mass spectrometry |
| WO2001027327A2 (en) * | 1999-10-08 | 2001-04-19 | Protogene Laboratories, Inc. | Method and apparatus for performing large numbers of reactions using array assembly |
| US7332275B2 (en) | 1999-10-13 | 2008-02-19 | Sequenom, Inc. | Methods for detecting methylated nucleotides |
| CA2507189C (en) | 2002-11-27 | 2018-06-12 | Sequenom, Inc. | Fragmentation-based methods and systems for sequence variation detection and discovery |
| WO2004097369A2 (en) * | 2003-04-25 | 2004-11-11 | Sequenom, Inc. | Fragmentation-based methods and systems for de novo sequencing |
| WO2005024068A2 (en) * | 2003-09-05 | 2005-03-17 | Sequenom, Inc. | Allele-specific sequence variation analysis |
| US20050149272A1 (en) * | 2003-09-10 | 2005-07-07 | Itshack Pe' Er | Method for sequencing polynucleotides |
| US20050196809A1 (en) * | 2004-03-05 | 2005-09-08 | Kelleher Neil L. | Identification and characterization of proteins using new database search modes |
| US20090075251A1 (en) * | 2004-03-24 | 2009-03-19 | Dimo Dietrich | Method for analysis of cytosine methylation |
| US7608394B2 (en) | 2004-03-26 | 2009-10-27 | Sequenom, Inc. | Methods and compositions for phenotype identification based on nucleic acid methylation |
| US9249456B2 (en) * | 2004-03-26 | 2016-02-02 | Agena Bioscience, Inc. | Base specific cleavage of methylation-specific amplification products in combination with mass analysis |
| US7785843B2 (en) * | 2004-06-23 | 2010-08-31 | Sequenom, Inc. | Target-specific compomers and methods of use |
| AU2005284980A1 (en) * | 2004-09-10 | 2006-03-23 | Sequenom, Inc. | Methods for long-range sequence analysis of nucleic acids |
| EP1836213A4 (en) * | 2004-12-13 | 2009-06-10 | Autogenomics Inc | COMPOSITIONS AND METHODS FOR NUCLEIC ACID ANALYSIS OF SEQUENCES HAVING INSERTIONS OR DELETIONS |
| US7765068B2 (en) | 2005-01-31 | 2010-07-27 | The Board Of Trustees Of The University Of Illinois | Identification and characterization of protein fragments |
| EP1762629B1 (en) | 2005-09-12 | 2009-11-11 | Roche Diagnostics GmbH | Detection of biological DNA |
| DE102006003415A1 (de) * | 2006-01-24 | 2007-08-02 | Siemens Ag | Verfahren zur Analyse einer Probe |
| EP3260556B1 (en) | 2006-05-31 | 2019-07-31 | Sequenom, Inc. | Methods for the extraction of nucleic acid from a sample |
| US7902345B2 (en) | 2006-12-05 | 2011-03-08 | Sequenom, Inc. | Detection and quantification of biomolecules using mass spectrometry |
| WO2009032781A2 (en) | 2007-08-29 | 2009-03-12 | Sequenom, Inc. | Methods and compositions for universal size-specific polymerase chain reaction |
| US7888127B2 (en) | 2008-01-15 | 2011-02-15 | Sequenom, Inc. | Methods for reducing adduct formation for mass spectrometry analysis |
| US8852864B2 (en) * | 2008-01-17 | 2014-10-07 | Sequenom Inc. | Methods and compositions for the analysis of nucleic acids |
| ES2990227T3 (es) | 2008-01-17 | 2024-11-29 | Sequenom Inc | Composiciones y procedimientos de análisis de ácido nucleico de secuencia única |
| CA2717320A1 (en) * | 2008-03-11 | 2009-09-17 | Sequenom, Inc. | Nucleic acid-based tests for prenatal gender determination |
| US20100063742A1 (en) * | 2008-09-10 | 2010-03-11 | Hart Christopher E | Multi-scale short read assembly |
| US8962247B2 (en) * | 2008-09-16 | 2015-02-24 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses |
| US8476013B2 (en) | 2008-09-16 | 2013-07-02 | Sequenom, Inc. | Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
| CN102203292B (zh) * | 2008-10-29 | 2014-06-25 | 南克森制药公司 | 通过质谱分析法测序核酸分子 |
| EP3181702B1 (en) | 2008-11-24 | 2019-04-17 | Sequenom, Inc. | Improving nucleic acid quantitation by compressing the dynamic range of high-abundance molecules |
| JP2012512665A (ja) * | 2008-12-19 | 2012-06-07 | アボット・ラボラトリーズ | ヒトｋ−ｒａｓのコドン１２−１３における突然変異の診断試験 |
| DE102009005845A1 (de) * | 2009-01-21 | 2010-07-22 | Friedrich-Schiller-Universität Jena | Verfahren zur Indentifizierung insbesondere unbekannter Substanzen durch Massenspektrometrie |
| WO2010091021A2 (en) * | 2009-02-03 | 2010-08-12 | Complete Genomics, Inc. | Oligomer sequences mapping |
| WO2010091023A2 (en) * | 2009-02-03 | 2010-08-12 | Complete Genomics, Inc. | Indexing a reference sequence for oligomer sequence mapping |
| WO2010091024A1 (en) * | 2009-02-03 | 2010-08-12 | Complete Genomics, Inc. | Oligomer sequences mapping |
| US20100279295A1 (en) * | 2009-03-18 | 2010-11-04 | Sequenom, Inc. | Use of thermostable endonucleases for generating reporter molecules |
| EP3514244B1 (en) | 2009-04-03 | 2021-07-07 | Sequenom, Inc. | Nucleic acid preparation methods |
| WO2010127045A2 (en) * | 2009-04-29 | 2010-11-04 | Complete Genomics, Inc. | Method and system for calling variations in a sample polynucleotide sequence with respect to a reference polynucleotide sequence |
| US12129514B2 (en) | 2009-04-30 | 2024-10-29 | Molecular Loop Biosolutions, Llc | Methods and compositions for evaluating genetic markers |
| EP2425240A4 (en) | 2009-04-30 | 2012-12-12 | Good Start Genetics Inc | METHOD AND COMPOSITION FOR EVALUATING GENETIC MARKERS |
| EP2449091A4 (en) | 2009-07-02 | 2012-12-05 | Verdezyne Inc | BIOLOGICAL METHODS FOR PREPARING ADIPIC ACID |
| AP3766A (en) | 2009-07-09 | 2016-07-31 | Du Pont | Engineered microorganisms with enhanced fermentation activity |
| US8889394B2 (en) * | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| WO2011041695A1 (en) * | 2009-10-02 | 2011-04-07 | Ibis Biosciences, Inc. | Determination of methylation status of polynucleotides |
| EP3088532B1 (en) | 2009-12-22 | 2019-10-30 | Sequenom, Inc. | Processes and kits for identifying aneuploidy |
| KR20120120500A (ko) * | 2010-02-18 | 2012-11-01 | 에프. 호프만-라 로슈 아게 | 폴리펩티드 서열 변이체의 측정 방법 |
| JP5738027B2 (ja) * | 2010-03-30 | 2015-06-17 | キヤノン株式会社 | 質量分析法 |
| US8412462B1 (en) | 2010-06-25 | 2013-04-02 | Annai Systems, Inc. | Methods and systems for processing genomic data |
| JP6222202B2 (ja) * | 2010-07-05 | 2017-11-01 | ソニー株式会社 | 生体情報処理方法および装置、並びに記録媒体 |
| JP5838557B2 (ja) | 2010-07-05 | 2016-01-06 | ソニー株式会社 | 生体情報処理方法および装置、並びに記録媒体 |
| EP3023503B1 (en) * | 2010-08-19 | 2017-04-05 | Erasmus University Medical Center Rotterdam | Methods for determining antibiotic resistance in microorganisms |
| WO2012031029A2 (en) | 2010-08-31 | 2012-03-08 | Lawrence Ganeshalingam | Method and systems for processing polymeric sequence data and related information |
| US9163281B2 (en) | 2010-12-23 | 2015-10-20 | Good Start Genetics, Inc. | Methods for maintaining the integrity and identification of a nucleic acid template in a multiplex sequencing reaction |
| JPWO2012111249A1 (ja) * | 2011-02-14 | 2014-07-03 | 学校法人麻布獣医学園 | 質量分析法における質量変化を検出する方法及び安定同位体標識タンパク質の絶対量の定量方法 |
| US20120230338A1 (en) | 2011-03-09 | 2012-09-13 | Annai Systems, Inc. | Biological data networks and methods therefor |
| WO2012149339A2 (en) | 2011-04-29 | 2012-11-01 | Sequenom, Inc. | Quantification of a minority nucleic acid species |
| US8728798B2 (en) | 2011-05-03 | 2014-05-20 | Verdezyne, Inc. | Biological methods for preparing adipic acid |
| US8343752B2 (en) | 2011-05-03 | 2013-01-01 | Verdezyne, Inc. | Biological methods for preparing adipic acid |
| US20140235474A1 (en) | 2011-06-24 | 2014-08-21 | Sequenom, Inc. | Methods and processes for non invasive assessment of a genetic variation |
| WO2013006733A2 (en) | 2011-07-06 | 2013-01-10 | Verdezyne, Inc. | Biological methods for preparing a fatty dicarboxylic acid |
| US9984198B2 (en) | 2011-10-06 | 2018-05-29 | Sequenom, Inc. | Reducing sequence read count error in assessment of complex genetic variations |
| CA2850785C (en) | 2011-10-06 | 2022-12-13 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| ES2886508T3 (es) | 2011-10-06 | 2021-12-20 | Sequenom Inc | Métodos y procedimientos para la evaluación no invasiva de variaciones genéticas |
| US10196681B2 (en) | 2011-10-06 | 2019-02-05 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10424394B2 (en) | 2011-10-06 | 2019-09-24 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US9367663B2 (en) | 2011-10-06 | 2016-06-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US8688388B2 (en) | 2011-10-11 | 2014-04-01 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3243908B1 (en) | 2011-10-11 | 2019-01-02 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CA2852665A1 (en) | 2011-10-17 | 2013-04-25 | Good Start Genetics, Inc. | Analysis methods |
| JP5750676B2 (ja) * | 2011-10-18 | 2015-07-22 | 株式会社島津製作所 | 細胞識別装置及びプログラム |
| WO2013109981A1 (en) | 2012-01-20 | 2013-07-25 | Sequenom, Inc. | Diagnostic processes that factor experimental conditions |
| HK1206055A1 (en) | 2012-03-02 | 2015-12-31 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US8209130B1 (en) | 2012-04-04 | 2012-06-26 | Good Start Genetics, Inc. | Sequence assembly |
| US8812422B2 (en) | 2012-04-09 | 2014-08-19 | Good Start Genetics, Inc. | Variant database |
| US10227635B2 (en) | 2012-04-16 | 2019-03-12 | Molecular Loop Biosolutions, Llc | Capture reactions |
| US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
| US10504613B2 (en) | 2012-12-20 | 2019-12-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| DK3663409T3 (da) | 2012-05-21 | 2021-12-13 | Sequenom Inc | Fremgangsmåder og processer til ikke-invasiv bedømmelse af genetiske variationer |
| AU2013277986B2 (en) | 2012-06-22 | 2016-12-01 | Annai Systems Inc. | System and method for secure, high-speed transfer of very large files |
| US10497461B2 (en) | 2012-06-22 | 2019-12-03 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20140004105A1 (en) | 2012-06-29 | 2014-01-02 | Sequenom, Inc. | Age-related macular degeneration diagnostics |
| US20140093873A1 (en) | 2012-07-13 | 2014-04-03 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
| CA2887094C (en) | 2012-10-04 | 2021-09-07 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10482994B2 (en) | 2012-10-04 | 2019-11-19 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| HUE052914T2 (hu) | 2012-12-19 | 2021-05-28 | Corvay Bioproducts Gmbh | Biológiai eljárások zsírdikarbonsav elõállítására |
| SG10201705057QA (en) | 2012-12-19 | 2017-07-28 | Verdezyne Inc | Biological methods for preparing a fatty dicarboxylic acid |
| US20130309666A1 (en) | 2013-01-25 | 2013-11-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20130189684A1 (en) | 2013-03-12 | 2013-07-25 | Sequenom, Inc. | Quantification of cell-specific nucleic acid markers |
| US9305756B2 (en) | 2013-03-13 | 2016-04-05 | Agena Bioscience, Inc. | Preparation enhancements and methods of use for MALDI mass spectrometry |
| HK1216655A1 (zh) | 2013-03-13 | 2016-11-25 | Sequenom, Inc. | 用於dna甲基化分析的引物 |
| WO2014152421A1 (en) | 2013-03-14 | 2014-09-25 | Good Start Genetics, Inc. | Methods for analyzing nucleic acids |
| PL2981921T3 (pl) | 2013-04-03 | 2023-05-08 | Sequenom, Inc. | Metody i procesy nieinwazyjnej oceny zmienności genetycznych |
| EP4604127A3 (en) | 2013-05-24 | 2025-12-03 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US8847799B1 (en) | 2013-06-03 | 2014-09-30 | Good Start Genetics, Inc. | Methods and systems for storing sequence read data |
| HUE042654T2 (hu) | 2013-06-21 | 2019-07-29 | Sequenom Inc | Eljárás genetikai variációk nem-invazív megállapítására |
| JP2015035212A (ja) * | 2013-07-29 | 2015-02-19 | アジレント・テクノロジーズ・インクＡｇｉｌｅｎｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | ターゲットシークエンシングパネルから変異を見つける方法 |
| US10726942B2 (en) | 2013-08-23 | 2020-07-28 | Complete Genomics, Inc. | Long fragment de novo assembly using short reads |
| IL304949B2 (en) | 2013-10-04 | 2025-09-01 | Sequenom Inc | Methods and processes for non-invasive assessment of genetic variations |
| EP3495496B1 (en) | 2013-10-07 | 2020-11-25 | Sequenom, Inc. | Methods and processes for non-invasive assessment of chromosome alterations |
| US11041203B2 (en) | 2013-10-18 | 2021-06-22 | Molecular Loop Biosolutions, Inc. | Methods for assessing a genomic region of a subject |
| US10851414B2 (en) | 2013-10-18 | 2020-12-01 | Good Start Genetics, Inc. | Methods for determining carrier status |
| US11365447B2 (en) | 2014-03-13 | 2022-06-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10513706B2 (en) | 2014-04-09 | 2019-12-24 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
| US11053548B2 (en) | 2014-05-12 | 2021-07-06 | Good Start Genetics, Inc. | Methods for detecting aneuploidy |
| US20150347676A1 (en) | 2014-05-30 | 2015-12-03 | Sequenom, Inc. | Chromosome representation determinations |
| WO2016019042A1 (en) | 2014-07-30 | 2016-02-04 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3180724B1 (en) * | 2014-08-15 | 2024-05-15 | Life Technologies Corporation | Methods and systems for detecting minor variants in a sample of genetic material |
| US20160048608A1 (en) | 2014-08-15 | 2016-02-18 | Good Start Genetics, Inc. | Systems and methods for genetic analysis |
| US11408024B2 (en) | 2014-09-10 | 2022-08-09 | Molecular Loop Biosciences, Inc. | Methods for selectively suppressing non-target sequences |
| WO2016040602A1 (en) * | 2014-09-11 | 2016-03-17 | Epicentre Technologies Corporation | Reduced representation bisulfite sequencing using uracil n-glycosylase (ung) and endonuclease iv |
| US10429399B2 (en) | 2014-09-24 | 2019-10-01 | Good Start Genetics, Inc. | Process control for increased robustness of genetic assays |
| US10892035B2 (en) | 2014-10-10 | 2021-01-12 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10000799B2 (en) | 2014-11-04 | 2018-06-19 | Boreal Genomics, Inc. | Methods of sequencing with linked fragments |
| JP6694635B2 (ja) * | 2014-12-26 | 2020-05-20 | 国立大学法人大阪大学 | マイクロｒｎａにおけるメチル化修飾部位を計測する方法 |
| EP4095261B1 (en) | 2015-01-06 | 2025-05-28 | Molecular Loop Biosciences, Inc. | Screening for structural variants |
| WO2016154046A2 (en) | 2015-03-20 | 2016-09-29 | Verdezyne, Inc. | Biological methods for preparing 3-hydroxypropionic acid |
| US10395759B2 (en) | 2015-05-18 | 2019-08-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for copy number variant detection |
| CN108026581A (zh) * | 2015-06-19 | 2018-05-11 | 剑桥企业有限公司 | 感染性疾病的诊断与治疗 |
| EP3378002A1 (en) | 2015-11-16 | 2018-09-26 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CA3014292A1 (en) | 2016-02-12 | 2017-08-17 | Regeneron Pharmaceuticals, Inc. | Methods and systems for detection of abnormal karyotypes |
| WO2017168331A1 (en) | 2016-03-28 | 2017-10-05 | Boreal Genomics, Inc. | Linked duplex fragment sequencing |
| US10961573B2 (en) | 2016-03-28 | 2021-03-30 | Boreal Genomics, Inc. | Linked duplex target capture |
| CN107423534B (zh) * | 2016-05-24 | 2021-08-06 | 郝柯 | 基因组拷贝数变异的检测方法和系统 |
| EP3464626B1 (en) | 2016-05-27 | 2022-04-06 | Sequenom, Inc. | Methods for detecting genetic variations |
| US10274440B2 (en) | 2016-06-22 | 2019-04-30 | International Business Machines Corporation | Method to facilitate investigation of chemical constituents in chemical analysis data |
| CA3030894A1 (en) | 2016-07-27 | 2018-02-01 | Sequenom, Inc. | Methods for non-invasive assessment of genomic instability |
| US11200963B2 (en) | 2016-07-27 | 2021-12-14 | Sequenom, Inc. | Genetic copy number alteration classifications |
| CN106355045B (zh) * | 2016-08-30 | 2019-03-15 | 天津诺禾致源生物信息科技有限公司 | 一种基于扩增子二代测序小片段插入缺失检测的方法及装置 |
| CN106611106B (zh) * | 2016-12-06 | 2019-05-03 | 北京荣之联科技股份有限公司 | 基因变异检测方法及装置 |
| JP7048609B2 (ja) | 2016-12-09 | 2022-04-05 | ボリアル ジェノミクス， インコーポレイテッド | 連結型ライゲーション |
| US11352662B2 (en) | 2017-01-20 | 2022-06-07 | Sequenom, Inc. | Sequence adapter manufacture and use |
| CA3198931A1 (en) | 2017-01-20 | 2018-07-26 | Sequenom, Inc. | Methods for non-invasive assessment of genetic alterations |
| US11929143B2 (en) | 2017-01-20 | 2024-03-12 | Sequenom, Inc | Methods for non-invasive assessment of copy number alterations |
| US11694768B2 (en) | 2017-01-24 | 2023-07-04 | Sequenom, Inc. | Methods and processes for assessment of genetic variations |
| JP7370862B2 (ja) | 2017-03-17 | 2023-10-30 | セクエノム， インコーポレイテッド | 遺伝子モザイク症のための方法およびプロセス |
| AU2018300069C1 (en) | 2017-07-11 | 2025-11-20 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
| CA3069697A1 (en) | 2017-07-13 | 2019-01-17 | Radici Chimica S.P.A. | Biological methods for modifying cellular carbon flux |
| WO2019028419A1 (en) | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES |
| WO2019051103A1 (en) * | 2017-09-06 | 2019-03-14 | Lawrence Livermore National Security, Llc | METHODS AND SYSTEMS FOR EXECUTING GENETICALLY MODIFIED PROTEIN ANALYSIS, AND ASSOCIATED MARKER PROTEIN GENETIC VARIATIONS AND DATABASES |
| US10426424B2 (en) | 2017-11-21 | 2019-10-01 | General Electric Company | System and method for generating and performing imaging protocol simulations |
| WO2019232520A1 (en) | 2018-06-01 | 2019-12-05 | Cerno Bioscience Llc | Mass spectral analysis of large molecules |
| WO2020039261A1 (en) | 2018-08-23 | 2020-02-27 | Boreal Genomics, Inc. | Linked target capture and ligation |
| WO2020060948A1 (en) | 2018-09-17 | 2020-03-26 | Levadura Biotechnology, Inc. | Production of cannabinoids in yeast using a fatty acid feedstock |
| CN109920485B (zh) * | 2018-12-29 | 2023-10-31 | 浙江安诺优达生物科技有限公司 | 对测序序列进行变异模拟的方法及其应用 |
| WO2020141464A1 (en) | 2019-01-03 | 2020-07-09 | Boreal Genomics, Inc. | Linked target capture |
| CA3126148A1 (en) | 2019-01-10 | 2020-07-16 | Travera LLC | Calibration of a functional biomarker instrument |
| EP3912007A4 (en) | 2019-01-10 | 2022-11-02 | Travera LLC | IDENTIFICATION OF CANCER THERAPIES |
| CA3126147A1 (en) | 2019-01-10 | 2020-07-16 | Travera LLC | Machine learning in functional cancer assays |
| KR20260039812A (ko) | 2019-02-06 | 2026-03-20 | 신톡스, 인크. | Il-2 콘쥬게이트 및 이의 사용 방법 |
| TWI723867B (zh) * | 2019-05-10 | 2021-04-01 | 中央研究院 | 用以產生高解析度圖譜的動態數據校正方法及裝置 |
| US20240395357A1 (en) | 2019-10-31 | 2024-11-28 | Sequenom, Inc. | Application of mosaicism ratio in multifetal gestations and personalized risk assessment |
| CN111304345A (zh) * | 2020-02-27 | 2020-06-19 | 中国人民解放军军事科学院军事医学研究院 | 幽门螺旋杆菌23S rRNA基因耐药突变的检测方法及其应用 |
| WO2021173909A1 (en) * | 2020-02-27 | 2021-09-02 | Monsanto Technology Llc | Methods for selecting inheritable edits |
| CN111477276B (zh) * | 2020-04-02 | 2020-12-15 | 上海之江生物科技股份有限公司 | 微生物的种特异共有序列的获得方法、装置及应用 |
| CN111662990B (zh) * | 2020-07-10 | 2025-02-11 | 内蒙古农业大学职业技术学院 | 一种用于定量检测猪瘟抗体不同水平的方法和引物对 |
| WO2022125997A1 (en) | 2020-12-11 | 2022-06-16 | The Broad Institute, Inc. | Method for duplex sequencing |
| CN117677833A (zh) | 2021-07-28 | 2024-03-08 | 约翰威利父子公司 | 自适应搜索质谱仪光谱分析 |
| CN114974416B (zh) * | 2022-07-15 | 2023-04-07 | 深圳雅济科技有限公司 | 一种检测相邻多核苷酸变异的方法及装置 |
| CN116758990B (zh) * | 2023-06-19 | 2025-07-29 | 赛纳生物科技(北京)有限公司 | 一种基因变异分析方法及系统 |
Family Cites Families (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US42112A (en) * | 1864-03-29 | Improvement in grain-drills | ||
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5173418A (en) | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
| US4762823A (en) | 1985-10-16 | 1988-08-09 | Sloan-Kettering Institute For Cancer Research | Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil |
| US5079342A (en) * | 1986-01-22 | 1992-01-07 | Institut Pasteur | Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits |
| US4826360A (en) * | 1986-03-10 | 1989-05-02 | Shimizu Construction Co., Ltd. | Transfer system in a clean room |
| EP0269520A3 (fr) | 1986-11-21 | 1988-08-24 | Institut Pasteur | Rétrovirus du type HIV-2 susceptible de provoquer le sida, et ses constituants antigéniques et nucléiques |
| FR2620049B2 (fr) * | 1986-11-28 | 1989-11-24 | Commissariat Energie Atomique | Procede de traitement, stockage et/ou transfert d'un objet dans une atmosphere de haute proprete, et conteneur pour la mise en oeuvre de ce procede |
| US4837726A (en) | 1987-06-19 | 1989-06-06 | Applied Biosystems, Inc. | Quantitation of chromatographic information |
| US4802102A (en) | 1987-07-15 | 1989-01-31 | Hewlett-Packard Company | Baseline correction for chromatography |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| US5003059A (en) * | 1988-06-20 | 1991-03-26 | Genomyx, Inc. | Determining DNA sequences by mass spectrometry |
| EP0395481A3 (en) | 1989-04-25 | 1991-03-20 | Spectra-Physics, Inc. | Method and apparatus for estimation of parameters describing chromatographic peaks |
| US5118937A (en) * | 1989-08-22 | 1992-06-02 | Finnigan Mat Gmbh | Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules |
| JPH05503423A (ja) * | 1990-01-12 | 1993-06-10 | スクリップス クリニック アンド リサーチ ファウンデーション | Ｄｎａ切断用核酸酵素 |
| NZ236819A (en) * | 1990-02-03 | 1993-07-27 | Max Planck Gesellschaft | Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions |
| IT1239733B (it) | 1990-02-23 | 1993-11-15 | Eniricerche Spa | Mutanti della proteasi neutra termostabili e mezzi e metodi per la loro preparazione |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| EP0531404B1 (en) * | 1990-05-09 | 1995-04-19 | Massachusetts Institute Of Technology | Ubiquitin-specific protease |
| US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| US5364759B2 (en) | 1991-01-31 | 1999-07-20 | Baylor College Medicine | Dna typing with short tandem repeat polymorphisms and identification of polymorphic short tandem repeats |
| US5210412A (en) * | 1991-01-31 | 1993-05-11 | Wayne State University | Method for analyzing an organic sample |
| WO1992013629A1 (en) | 1991-01-31 | 1992-08-20 | Wayne State University | A method for analyzing an organic sample |
| US5578443A (en) | 1991-03-06 | 1996-11-26 | Regents Of The University Of Minnesota | DNA sequence-based HLA typing method |
| CA2066556A1 (en) * | 1991-04-26 | 1992-10-27 | Toyoji Sawayanagi | Alkaline protease, method for producing the same, use thereof and microorganism producing the same |
| US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US5436150A (en) * | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| US5646020A (en) * | 1992-05-14 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | Hammerhead ribozymes for preferred targets |
| ATE427493T1 (de) * | 1992-05-29 | 2009-04-15 | Univ Rockefeller | Verfahren zur bestimmung der folge von peptiden unter verwendung eines massenspektrometers |
| US5792664A (en) | 1992-05-29 | 1998-08-11 | The Rockefeller University | Methods for producing and analyzing biopolymer ladders |
| US5440119A (en) * | 1992-06-02 | 1995-08-08 | Labowsky; Michael J. | Method for eliminating noise and artifact peaks in the deconvolution of multiply charged mass spectra |
| WO1994000562A1 (en) | 1992-06-24 | 1994-01-06 | The Mt. Sinai School Of Medicine Of The City University Of New York | A novel human immunodeficiency virus |
| US5700672A (en) * | 1992-07-23 | 1997-12-23 | Stratagene | Purified thermostable pyrococcus furiousus DNA ligase |
| EP0596205A3 (en) | 1992-11-03 | 1996-02-21 | Hewlett Packard Co | Bench supervisor system. |
| US5795714A (en) | 1992-11-06 | 1998-08-18 | Trustees Of Boston University | Method for replicating an array of nucleic acid probes |
| US6436635B1 (en) | 1992-11-06 | 2002-08-20 | Boston University | Solid phase sequencing of double-stranded nucleic acids |
| US5503980A (en) * | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| US5422253A (en) | 1992-12-07 | 1995-06-06 | Wisconsin Alumni Research Foundation | Method of site specific nucleic acid cleavage |
| US6194144B1 (en) * | 1993-01-07 | 2001-02-27 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
| CA2153387A1 (en) * | 1993-01-07 | 1994-07-21 | Hubert Koester | Dna sequencing by mass spectrometry |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US6074823A (en) * | 1993-03-19 | 2000-06-13 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
| ATE220114T1 (de) * | 1993-03-19 | 2002-07-15 | Sequenom Inc | Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease |
| US5604098A (en) * | 1993-03-24 | 1997-02-18 | Molecular Biology Resources, Inc. | Methods and materials for restriction endonuclease applications |
| AU681650B2 (en) | 1993-03-24 | 1997-09-04 | Molecular Biology Resources, Inc. | Dinucleotide restriction endonuclease preparations and methods of use |
| CA2122203C (en) * | 1993-05-11 | 2001-12-18 | Melinda S. Fraiser | Decontamination of nucleic acid amplification reactions |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5861242A (en) * | 1993-06-25 | 1999-01-19 | Affymetrix, Inc. | Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same |
| FR2710075B1 (fr) * | 1993-09-15 | 1995-10-27 | Bio Merieux | Réactif et procédé pour la détection d'une séquence nucléotidique avec amplification de signal. |
| EP0765401B1 (en) | 1993-11-17 | 2001-02-21 | Amersham Pharmacia Biotech UK Limited | Primer extension mass spectroscopy nucleic acid sequencing method |
| US5908779A (en) * | 1993-12-01 | 1999-06-01 | University Of Connecticut | Targeted RNA degradation using nuclear antisense RNA |
| US5714330A (en) * | 1994-04-04 | 1998-02-03 | Lynx Therapeutics, Inc. | DNA sequencing by stepwise ligation and cleavage |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5853979A (en) | 1995-06-30 | 1998-12-29 | Visible Genetics Inc. | Method and system for DNA sequence determination and mutation detection with reference to a standard |
| US5498545A (en) * | 1994-07-21 | 1996-03-12 | Vestal; Marvin L. | Mass spectrometer system and method for matrix-assisted laser desorption measurements |
| US5453613A (en) | 1994-10-21 | 1995-09-26 | Hewlett Packard Company | Mass spectra interpretation system including spectra extraction |
| US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
| US6428955B1 (en) | 1995-03-17 | 2002-08-06 | Sequenom, Inc. | DNA diagnostics based on mass spectrometry |
| US5858705A (en) * | 1995-06-05 | 1999-01-12 | Human Genome Sciences, Inc. | Polynucleotides encoding human DNA ligase III and methods of using these polynucleotides |
| AU758454B2 (en) | 1995-04-11 | 2003-03-20 | Sequenom, Inc. | Solid phase sequencing of biopolymers |
| US5869240A (en) * | 1995-05-19 | 1999-02-09 | Perseptive Biosystems, Inc. | Methods and apparatus for sequencing polymers with a statistical certainty using mass spectrometry |
| US5753439A (en) * | 1995-05-19 | 1998-05-19 | Trustees Of Boston University | Nucleic acid detection methods |
| US5874283A (en) * | 1995-05-30 | 1999-02-23 | John Joseph Harrington | Mammalian flap-specific endonuclease |
| JP3790797B2 (ja) * | 1995-07-11 | 2006-06-28 | フォーファス | グリコシラーゼによる候補座位のヌクレオチド配列の検出 |
| US6146854A (en) | 1995-08-31 | 2000-11-14 | Sequenom, Inc. | Filtration processes, kits and devices for isolating plasmids |
| US5869242A (en) * | 1995-09-18 | 1999-02-09 | Myriad Genetics, Inc. | Mass spectrometry to assess DNA sequence polymorphisms |
| US6190865B1 (en) * | 1995-09-27 | 2001-02-20 | Epicentre Technologies Corporation | Method for characterizing nucleic acid molecules |
| US6090549A (en) * | 1996-01-16 | 2000-07-18 | University Of Chicago | Use of continuous/contiguous stacking hybridization as a diagnostic tool |
| US6090606A (en) * | 1996-01-24 | 2000-07-18 | Third Wave Technologies, Inc. | Cleavage agents |
| US5830712A (en) | 1996-02-06 | 1998-11-03 | Allelix Biopharmaceuticals Inc. | Selective template deletion method |
| US5686656A (en) | 1996-02-27 | 1997-11-11 | Aviv Amirav | Method and device for the introduction of a sample into a gas chromatograph |
| CA2248084A1 (en) * | 1996-03-04 | 1997-09-12 | Genetrace Systems, Inc. | Methods of screening nucleic acids using mass spectrometry |
| AU2217597A (en) | 1996-03-18 | 1997-10-22 | Sequenom, Inc. | Dna sequencing by mass spectrometry |
| EP0863858B1 (en) | 1996-04-08 | 2004-02-04 | Glaxo Group Limited | Mass-based encoding and qualitative analysis of combinatorial libraries |
| US5928906A (en) * | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6022688A (en) * | 1996-05-13 | 2000-02-08 | Sequenom, Inc. | Method for dissociating biotin complexes |
| US5786146A (en) * | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| ATE312169T1 (de) * | 1996-06-10 | 2005-12-15 | Novozymes Inc | 5-aminolevulinsaure synthase aus aspergillus oryzae und dafuer kodierende nukleinsaeure |
| FR2749662B1 (fr) | 1996-06-11 | 1998-08-28 | Elf Aquitaine | Laboratoire robotise d'analyses d'echantillons |
| AU3891097A (en) | 1996-07-24 | 1998-02-10 | Michelle M. Hanna | Base-protected nucleotide analogs with protected thiol groups |
| US5928870A (en) * | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
| US5885841A (en) * | 1996-09-11 | 1999-03-23 | Eli Lilly And Company | System and methods for qualitatively and quantitatively comparing complex admixtures using single ion chromatograms derived from spectroscopic analysis of such admixtures |
| GB9618960D0 (en) * | 1996-09-11 | 1996-10-23 | Medical Science Sys Inc | Proteases |
| WO1998012355A1 (en) | 1996-09-19 | 1998-03-26 | Genetrace Systems | Methods of preparing nucleic acids for mass spectrometric analysis |
| US5965363A (en) * | 1996-09-19 | 1999-10-12 | Genetrace Systems Inc. | Methods of preparing nucleic acids for mass spectrometric analysis |
| US5777324A (en) * | 1996-09-19 | 1998-07-07 | Sequenom, Inc. | Method and apparatus for maldi analysis |
| US5864137A (en) * | 1996-10-01 | 1999-01-26 | Genetrace Systems, Inc. | Mass spectrometer |
| US6024925A (en) * | 1997-01-23 | 2000-02-15 | Sequenom, Inc. | Systems and methods for preparing low volume analyte array elements |
| US6140053A (en) | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
| ES2215241T3 (es) | 1996-11-06 | 2004-10-01 | Sequenom, Inc. | Procedimiento de espectrometria de masa. |
| DE69738206T2 (de) * | 1996-11-06 | 2008-07-17 | Sequenom, Inc., San Diego | DNA-Diagnostik mittels Massenspektrometrie |
| US6133436A (en) | 1996-11-06 | 2000-10-17 | Sequenom, Inc. | Beads bound to a solid support and to nucleic acids |
| US5900481A (en) * | 1996-11-06 | 1999-05-04 | Sequenom, Inc. | Bead linkers for immobilizing nucleic acids to solid supports |
| US6297006B1 (en) | 1997-01-16 | 2001-10-02 | Hyseq, Inc. | Methods for sequencing repetitive sequences and for determining the order of sequence subfragments |
| US6059724A (en) * | 1997-02-14 | 2000-05-09 | Biosignal, Inc. | System for predicting future health |
| US6994960B1 (en) * | 1997-05-28 | 2006-02-07 | The Walter And Eliza Hall Institute Of Medical Research | Nucleic acid diagnostics based on mass spectrometry or mass separation and base specific cleavage |
| US5976806A (en) | 1997-06-25 | 1999-11-02 | Pioneer Hi-Bred International, Inc. | DNA ligase assay |
| US5975492A (en) | 1997-07-14 | 1999-11-02 | Brenes; Arthur | Bellows driver slot valve |
| US6207370B1 (en) | 1997-09-02 | 2001-03-27 | Sequenom, Inc. | Diagnostics based on mass spectrometric detection of translated target polypeptides |
| US5888795A (en) * | 1997-09-09 | 1999-03-30 | Becton, Dickinson And Company | Thermostable uracil DNA glycosylase and methods of use |
| US6112161A (en) | 1997-09-17 | 2000-08-29 | Hewlett-Packard | Method, apparatus, and article of manufacture for enhanced intergration of signals |
| AU9400398A (en) * | 1997-09-19 | 1999-04-05 | Genetrace Systems, Inc. | Dna typing by mass spectrometry with polymorphic dna repeat markers |
| US6485944B1 (en) | 1997-10-10 | 2002-11-26 | President And Fellows Of Harvard College | Replica amplification of nucleic acid arrays |
| US5932451A (en) | 1997-11-19 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Method for unbiased mRNA amplification |
| US5948902A (en) | 1997-11-20 | 1999-09-07 | South Alabama Medical Science Foundation | Antisense oligonucleotides to human serine/threonine protein phosphatase genes |
| DE19754482A1 (de) * | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| DK1036198T3 (da) * | 1997-12-08 | 2013-01-02 | California Inst Of Techn | Fremgangsmåde til fremstilling af polynukleotid- og polypeptidsekvenser |
| US6268131B1 (en) * | 1997-12-15 | 2001-07-31 | Sequenom, Inc. | Mass spectrometric methods for sequencing nucleic acids |
| DE19803309C1 (de) * | 1998-01-29 | 1999-10-07 | Bruker Daltonik Gmbh | Massenspektrometrisches Verfahren zur genauen Massenbestimmung unbekannter Ionen |
| US6054276A (en) * | 1998-02-23 | 2000-04-25 | Macevicz; Stephen C. | DNA restriction site mapping |
| NO311111B1 (no) | 1998-04-03 | 2001-10-08 | Geir H Soerland | Metode for bestemmelse av mengden av fett og vann i en biologisk pröve |
| JP3575295B2 (ja) | 1998-04-15 | 2004-10-13 | 住友電装株式会社 | 電気接続用コネクタのプラグ |
| WO1999054501A1 (en) | 1998-04-22 | 1999-10-28 | Enterprise Ireland Trading As Bioresearch Ireland | A method for the characterisation of nucleic acid molecules involving generation of extendible upstream dna fragments resulting from the cleavage of nucleic acid at an abasic site |
| US6723564B2 (en) * | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
| US20030017483A1 (en) * | 1998-05-12 | 2003-01-23 | Ecker David J. | Modulation of molecular interaction sites on RNA and other biomolecules |
| US6099553A (en) | 1998-05-21 | 2000-08-08 | Applied Medical Resources Corporation | Suture clinch |
| US6104028A (en) * | 1998-05-29 | 2000-08-15 | Genetrace Systems Inc. | Volatile matrices for matrix-assisted laser desorption/ionization mass spectrometry |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| JP2000067805A (ja) * | 1998-08-24 | 2000-03-03 | Hitachi Ltd | 質量分析装置 |
| ATE431428T1 (de) | 1998-10-01 | 2009-05-15 | Variagenics Inc | Ein verfahren zur analyse von polynukleotiden |
| US6440705B1 (en) | 1998-10-01 | 2002-08-27 | Vincent P. Stanton, Jr. | Method for analyzing polynucleotides |
| US6270835B1 (en) | 1999-10-07 | 2001-08-07 | Microcoating Technologies, Inc. | Formation of this film capacitors |
| US6331427B1 (en) | 1999-03-26 | 2001-12-18 | Millennium Pharmaceuticals, Inc. | Protease homologs |
| US20020009394A1 (en) * | 1999-04-02 | 2002-01-24 | Hubert Koster | Automated process line |
| US6309833B1 (en) | 1999-04-12 | 2001-10-30 | Nanogen/Becton Dickinson Partnership | Multiplex amplification and separation of nucleic acid sequences on a bioelectronic microchip using asymmetric structures |
| US6994969B1 (en) * | 1999-04-30 | 2006-02-07 | Methexis Genomics, N.V. | Diagnostic sequencing by a combination of specific cleavage and mass spectrometry |
| ATE298004T1 (de) * | 1999-04-30 | 2005-07-15 | Methexis Genomics N V | Diagnostische sequenzierung durch eine kombination von spezifischer spaltung und massenspektrometrie |
| US7332275B2 (en) | 1999-10-13 | 2008-02-19 | Sequenom, Inc. | Methods for detecting methylated nucleotides |
| US6475736B1 (en) | 2000-05-23 | 2002-11-05 | Variagenics, Inc. | Methods for genetic analysis of DNA using biased amplification of polymorphic sites |
| EP1179589A1 (en) | 2000-08-08 | 2002-02-13 | F. Hoffmann-La Roche Ag | MMX-1, a member of the family of human cancer/testis antigens, a protein encoded thereby and a process for determining whether a tumor sample has metastatic potential |
| US20030027169A1 (en) * | 2000-10-27 | 2003-02-06 | Sheng Zhang | One-well assay for high throughput detection of single nucleotide polymorphisms |
| DE10061348C2 (de) * | 2000-12-06 | 2002-10-24 | Epigenomics Ag | Verfahren zur Quantifizierung von Cytosin-Methylierungen in komplex amplifizierter genomischer DNA |
| DE10112515B4 (de) * | 2001-03-09 | 2004-02-12 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungsmustern mit hoher Sensitivität |
| US20030013099A1 (en) * | 2001-03-19 | 2003-01-16 | Lasek Amy K. W. | Genes regulated by DNA methylation in colon tumors |
| US7056663B2 (en) * | 2001-03-23 | 2006-06-06 | California Pacific Medical Center | Prognostic methods for breast cancer |
| US6522477B2 (en) * | 2001-04-17 | 2003-02-18 | Karl Storz Imaging, Inc. | Endoscopic video camera with magnetic drive focusing |
| US20020155587A1 (en) | 2001-04-20 | 2002-10-24 | Sequenom, Inc. | System and method for testing a biological sample |
| EP1386005A1 (en) * | 2001-04-20 | 2004-02-04 | Karolinska Innovations AB | Methods for high throughput genome analysis using restriction site tagged microarrays |
| DE10130800B4 (de) * | 2001-06-22 | 2005-06-23 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität |
| CN1656233A (zh) | 2001-07-15 | 2005-08-17 | 凯克研究生院 | 利用切割剂扩增核酸片段 |
| JP2003245087A (ja) | 2001-11-22 | 2003-09-02 | Sankyo Co Ltd | 遺伝子診断方法 |
| DE10201138B4 (de) * | 2002-01-08 | 2005-03-10 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungsmustern durch exponentielle Ligation hybridisierter Sondenoligonukleotide (MLA) |
| AU2003220291A1 (en) | 2002-03-15 | 2003-09-29 | Epigenomics Ag | Discovery and diagnostic methods using 5-methylcytosine dna glycosylase |
| US7364897B2 (en) * | 2002-04-11 | 2008-04-29 | Sequenom, Inc. | Methods and devices for performing chemical reactions on a solid support |
| US20040014101A1 (en) * | 2002-05-03 | 2004-01-22 | Pel-Freez Clinical Systems, Inc. | Separating and/or identifying polymorphic nucleic acids using universal bases |
| CA2507189C (en) | 2002-11-27 | 2018-06-12 | Sequenom, Inc. | Fragmentation-based methods and systems for sequence variation detection and discovery |
| WO2004097369A2 (en) * | 2003-04-25 | 2004-11-11 | Sequenom, Inc. | Fragmentation-based methods and systems for de novo sequencing |
| US20050009059A1 (en) | 2003-05-07 | 2005-01-13 | Affymetrix, Inc. | Analysis of methylation status using oligonucleotide arrays |
| US8150626B2 (en) | 2003-05-15 | 2012-04-03 | Illumina, Inc. | Methods and compositions for diagnosing lung cancer with specific DNA methylation patterns |
| US20050026183A1 (en) * | 2003-05-15 | 2005-02-03 | Jian-Bing Fan | Methods and compositions for diagnosing conditions associated with specific DNA methylation patterns |
| US20040253141A1 (en) | 2003-06-16 | 2004-12-16 | Schembri Carol T. | Apparatus and method for nucleic acid spatial ordering |
| WO2005024068A2 (en) * | 2003-09-05 | 2005-03-17 | Sequenom, Inc. | Allele-specific sequence variation analysis |
| CA2542542C (en) * | 2003-10-21 | 2015-09-15 | Orion Genomics Llc | Method of detecting a quantity of methylation at a locus |
| US7608394B2 (en) | 2004-03-26 | 2009-10-27 | Sequenom, Inc. | Methods and compositions for phenotype identification based on nucleic acid methylation |
| US9249456B2 (en) | 2004-03-26 | 2016-02-02 | Agena Bioscience, Inc. | Base specific cleavage of methylation-specific amplification products in combination with mass analysis |
| AU2005284980A1 (en) * | 2004-09-10 | 2006-03-23 | Sequenom, Inc. | Methods for long-range sequence analysis of nucleic acids |
-
2003
- 2003-11-26 CA CA2507189A patent/CA2507189C/en not_active Expired - Fee Related
- 2003-11-26 EP EP03796490.5A patent/EP1613723B1/en not_active Expired - Lifetime
- 2003-11-26 JP JP2004557369A patent/JP4786904B2/ja not_active Expired - Fee Related
- 2003-11-26 AU AU2003298733A patent/AU2003298733B2/en not_active Ceased
- 2003-11-26 US US10/723,365 patent/US7820378B2/en not_active Expired - Fee Related
- 2003-11-26 WO PCT/US2003/037931 patent/WO2004050839A2/en not_active Ceased
- 2003-11-26 CN CN2003801092195A patent/CN1774511B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20050112590A1 (en) | 2005-05-26 |
| JP2006515987A (ja) | 2006-06-15 |
| AU2003298733A1 (en) | 2004-06-23 |
| HK1087436A1 (en) | 2006-10-13 |
| EP1613723B1 (en) | 2013-05-15 |
| US7820378B2 (en) | 2010-10-26 |
| WO2004050839A3 (en) | 2006-02-09 |
| WO2004050839A2 (en) | 2004-06-17 |
| CN1774511B (zh) | 2013-08-21 |
| AU2003298733B2 (en) | 2009-06-18 |
| CN1774511A (zh) | 2006-05-17 |
| EP1613723A4 (en) | 2010-06-09 |
| CA2507189A1 (en) | 2004-06-17 |
| EP1613723A2 (en) | 2006-01-11 |
| JP4786904B2 (ja) | 2011-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2507189C (en) | Fragmentation-based methods and systems for sequence variation detection and discovery | |
| AU2004235331B2 (en) | Fragmentation-based methods and systems for De Novo sequencing | |
| AU2008240143B2 (en) | Comparative sequence analysis processes and systems | |
| US20200318169A1 (en) | Products and processes for multiplex nucleic acid identification | |
| US20060073501A1 (en) | Methods for long-range sequence analysis of nucleic acids | |
| EP1173622B1 (en) | Diagnostic sequencing by a combination of specific cleavage and mass spectrometry | |
| US6994969B1 (en) | Diagnostic sequencing by a combination of specific cleavage and mass spectrometry | |
| US9394565B2 (en) | Allele-specific sequence variation analysis | |
| HK1087436B (en) | Fragmentation-based methods for sequence variation detection and discovery | |
| HK1140264B (en) | Comparative sequence analysis processes and systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210831 |
|
| MKLA | Lapsed |
Effective date: 20191126 |